A Study of Ferric Citrate to Improve Inflammation and Lipid Levels
The Effect of Ferric Citrate on Inflammation and Lipid Levels in Patients on Hemodialysis
Sponsor: Keryx Biopharmaceuticals
Terminated
38 enrolled, 19 completed the study when loss of funding occurred
Other Chronic Inflammation trials with similar outcome
A PHASE4 clinical study on Chronic Inflammation and End Stage Renal Disease, this trial is terminated or withdrawn. The trial is conducted by Keryx Biopharmaceuticals and has accumulated 8 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
May 2023 — Jul 2024 [monthly]
Terminated PHASE4
Status: Unknown Status → Terminated
-
Jan 2021 — May 2023 [monthly]
Unknown Status PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE4
▶ Show 3 earlier versions
-
Feb 2018 — Jun 2018 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Feb 2017 — Feb 2018 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Jul 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Keryx Biopharmaceuticals
- Winthrop University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .